Summary
54 / 100 · Bulios Score
What speaks for it
- Revenue grew by 367% a year over the last 3 years.
- It holds more cash than debt: $33.4M against $12.2M.
- Analysts expect revenue to grow by 44% this fiscal year.
- Out of every 100 USD of revenue, 12 USD is left as free cash.
What to watch
- The share price is above the Bulios Fair Price.
- The price moves much more than the market (beta 1.63).
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 107.4 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 367% a year over the last 3 years. For the next fiscal year analysts expect revenue to grow by 44%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 8.8 USD
- Research and development 18 USD
- Sales and administration 66 USD
- Taxes and other 1.0 USD
- Net profit 5.9 USD
Net profit, industry median (Biotechnology) -9.2 USD
Out of every 100 USD of revenue, 5.9 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 10
- Hold 2
- Sell 0
Today's price within the analysts' price targets
The average target of $42.25 is 65% above today's price. 83% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2023By product
- Other Revenue 51%
- Product 49%
By region
The company reports no revenue by region.
Other Revenue brings in 51% of revenue.
Segments in detail